COLUMBIA, Md., Sept 28, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- -- Celsion Corporation (Nasdaq: CLSN) announced today initiation of a nationwide enrollment program in its pivotal Phase I/II DIGNITY clinical trial evaluating the use of ThermoDox(R) in combination with hyperthermia for the treatment of Recurrent Chest Wall (RCW) Breast...
ANDOVER, Mass. & COLUMBIA, Md., Sep 23, 2009 (BUSINESS WIRE) -- Royal Philips Electronics (NYSE: PHG; AEX: PHI) and Celsion Corporation
(NASDAQ: CLSN) today announced that their joint research program to
evaluate ThermoDox(R) in combination with MR-HIFU (Magnetic Resonance
guided High Intensity Focused Ultrasound) as a combi...
COLUMBIA, Md., Sep 21, 2009 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ:CLSN) announced today the Data Safety
Monitoring Board ("DSMB") has reviewed the safety data from the first
group of patients enrolled in its pivotal ThermoDox(R) Phase III clinical
trial for primary liver cancer ("HEAT study") and has recommended tha...
COLUMBIA, Md., Sep 16, 2009 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ:CLSN) announced today the Company's DIGNITY
clinical trial evaluating the use of ThermoDox(R) in combination with
hyperthermia for the treatment of Recurrent Chest Wall (RCW) Breast
Cancer was aired during commercial breaks on Good Morning America and...
COLUMBIA, Md. & NEW YORK, Sep 14, 2009 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ:CLSN) and the American Liver Foundation
(ALF) announced today that they have formed a partnership to provide
education to physicians and liver patients about the treatment options
for hepatocellular carcinoma (commonly referred to as primar...
COLUMBIA, Md., Sep 02, 2009 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that Michael H.
Tardugno, Celsion's President and CEO, will present at the Rodman &
Renshaw 11th Annual Healthcare Conference on Wednesday, September 9th at
10:50 A.M. ET at the New York Palace Hotel in New York City.
A live au...
COLUMBIA, Md., Aug 17, 2009 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ:CLSN), a leading oncology drug development
company, today announced that the FDA has provided the Company with
positive guidance at a Type C Chemistry Manufacturing and Controls
("CMC") meeting recently held at the FDA's Office of New Drug Quality
...
COLUMBIA, Md., Aug 05, 2009 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ:CLSN), a leading oncology drug development
company, today announced financial results for the second quarter ended
June 30, 2009.
"In the second quarter of 2009 we made excellent progress towards the
completion of enrollment in the ThermoDox(R) globa...
COLUMBIA, Md., Jul 31, 2009 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ:CLSN), a biotechnology drug development
company that is leveraging its heat sensitive liposomal technology
platform to encapsulate and deliver high concentrations of proven
chemotherapeutics, today announced that it would hold a conference call
...
COLUMBIA, Md., Jul 27, 2009 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ: CLSN) and Yakult Honsha Co., Ltd. (Tokyo:
2267) announced today that Celsion's global Phase III ThermoDox trial
for the treatment of primary liver cancer will be extended to Japan by
Yakult's expertise. This is an important step towards a potential
...
COLUMBIA, Md., Jun 08, 2009 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that Michael H.
Tardugno, Celsion's President and CEO, will present at the 8th Annual
Needham Life Sciences Conference on Wednesday, June 10th at 2:00 P.M. ET
at the New York Palace Hotel in New York City. The Needham Life Scien...
COLUMBIA, Md., Jun 03, 2009 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company has
received $15 million from Boston Scientific for the previously reported
sale of its Prolieve(R) Assets. This payment was the third and final
payment to Celsion for a total of $60 million.
"The proceeds from...
COLUMBIA, Md., May 12, 2009 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ:CLSN), a leading oncology drug development
company, today announced financial results for its first quarter ended
March 31, 2009.
"We have made substantial progress moving our lead oncology drug
ThermoDox closer to commercialization," commented Micha...
COLUMBIA, Md., May 11, 2009 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ: CLSN), a biotechnology drug development
company that is leveraging its heat sensitive liposomal technology
platform to encapsulate and deliver high concentrations of proven
chemotherapeutics, will hold its Annual Meeting of Stockholders on
Fr...
COLUMBIA, Md., May 11, 2009 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that Professor David
Needham Ph.D., Department of Engineering and Material Science, Duke
University, will deliver a keynote address entitled "Design and Testing
of Novel Thermally Sensitive Liposomal Formulations for Treatment o...
COLUMBIA, Md., May 08, 2009 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ: CLSN), a biotechnology drug development
company that is leveraging its heat sensitive liposomal technology
platform to encapsulate and deliver high concentrations of proven
chemotherapeutics, today announced that it would hold a conference call
...
COLUMBIA, Md., Apr 27, 2009 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development
company, announced today the enrollment of its first patient in the
Phase I/II open label, dose escalating DIGNITY trial to evaluate the
safety and efficacy of ThermoDox with hyperthermia for the treatment o...
COLUMBIA, Md., Apr 06, 2009 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ: CLSN) today announced that promising Phase
I clinical results evaluating ThermoDox for the treatment of recurrent
chest wall (RCW) breast cancer were presented by Duke University
investigators on Sunday, April 5 at the 2009 Annual Meeting of the
...
COLUMBIA, Md., Apr 01, 2009 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ:CLSN), a leading oncology drug development
company, today announced that three abstracts on the Company's
proprietary thermosensitive liposome technology and ThermoDox? will be
presented at the Society for Thermal Medicine Annual Meeting, April 3-7,
...
COLUMBIA, Md., Mar 30, 2009 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ:CLSN), a leading oncology drug development
company, announced that promising Phase 1 ThermoDox clinical results in
hepatocellular carcinoma (HCC) or primary liver cancer have been
published in the peer-reviewed medical journal Expert Opinion on
...
